Kenya, March 16 -- CMS International Development and Management, a wholly-owned subsidiary of CMS, had secured an exclusive licence for the drug from Zydus in 2020. Desidustat, an oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI), promotes red blood cell production by boosting endogenous erythropoietin and improving iron availability, targeting anaemia in Chronic Kidney Disease (CKD) patients.

The drug is marketed in India under the brand name Oxemia, which has treated over 1 lakh (100,000) CKD patients since its 2022 launch. With an estimated 120 million CKD patients in China, there is significant unmet demand, particularly among non-dialysis patients, with only 8.2% achieving target haemoglobin levels.

Oral Desidust...